Despite the great advances that have been made in oncology, many cancers remain multi-resistant, without an effective therapeutic solution. THERAtRAME has positioned itself in the development of new medicines targeting changes in transfer RNAs, a process whose importance has recently been revealed in resistant cancers. This innovation offers important opportunities for patients. However, the industrial and commercial success of this initiative depends heavily on the ability to position these new treatments in patients: identify patients who may or may not benefit from new therapies. The aim of the EpiCare project is to define strategic biomarkers, through the development of innovative strategies typically involving artificial intelligence, to position new medicines targeting RNA epitranscriptomics and to market a range of tools for firms active in this field. EpiCare is based on a paradigm shift from a "target-centered" approach to a "patient-centered" approach.